The Scientific Frontier

Pfizer

3 articles

Pfizer's giant hand shaking Metsera's smaller hand, symbolizing a $4.9 billion acquisition deal amidst a backdrop of glowing drug molecules and market growth charts.
Health & Medicine

Pfizer acquires Metsera in $4.9B deal amid biotech boom

Pfizer will pay $4.9 billion to acquire Metsera, a company whose shares debuted at just $18, after its lead obesity candidate showed 11.3% weight loss in early trials, according to Biospace . This mul

Maria Flores·June 29, 2026
A scientist in a futuristic lab examining a holographic display of a triple hormone receptor drug, representing Pfizer's new obesity treatment.
Cosmos & Physics

Pfizer advances monthly obesity drug targeting triple hormone receptors

Pfizer is advancing a monthly weight-loss injection, danuglipron, having announced positive early-stage data.

Dr. Evelyn Reed·June 7, 2026
Scientists in a futuristic lab analyzing bispecific antibody data, representing advancements in lung cancer treatment presented at ASCO.
Computational Science & Software

Pfizer Shares Updated Lung Cancer Bispecifics Data at ASCO

At the ASCO Annual Meeting, updated Phase 2 data for Pfizer's bispecific antibody PF-08634404 demonstrated activity as monotherapy in first-line PD-L1-expressing non-small cell lung cancer.

Yasmin Haddad·May 31, 2026